Related Experiment Videos
Beta-blockers in left ventricular systolic dysfunction--from evidence to practice.
Syamasis Bandyopadhyay1, M Sinead O'Mahony
1University Department of Geriatric Medicine, Llandough Hospital, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX, UK.
Age and Ageing
|February 19, 2002
Summary
Beta-blockers significantly reduce mortality in heart failure patients. This review examines the evidence and practicalities of using beta-blockers in elderly heart failure patients despite clinician reluctance.
Area of Science:
- Cardiology
- Geriatric Medicine
- Pharmacology
Background:
- Heart failure accounts for 5% of hospital admissions.
- Incidence increases significantly in the elderly population (>10 per 1000 for those >=85 years).
- Beta-blockers demonstrate a 36% mortality reduction when added to ACE inhibitors.
Purpose of the Study:
- To review the evidence for beta-blocker use in elderly heart failure patients.
- To explore the practical challenges of prescribing beta-blockers in this demographic.
Main Methods:
- Literature review of existing studies on beta-blockers in heart failure.
- Analysis of evidence specifically for older adult populations.
- Discussion of clinical implementation and barriers.
Main Results:
- Overwhelming evidence supports beta-blocker efficacy in reducing mortality.
- Clinicians exhibit reluctance in prescribing beta-blockers for heart failure, particularly in older patients.
- Practical considerations for safe and effective use in the elderly are explored.
Conclusions:
- Despite proven benefits, beta-blocker use in elderly heart failure patients remains suboptimal.
- Further research and clinical guidance are needed to overcome prescribing hesitancy.
- Optimizing beta-blocker therapy can improve outcomes for older adults with heart failure.